From October 1, 2025 to December 31, 2025, the company has repurchased 1,479,000 shares, representing 0.17% for $1,481.37 million. With this, the company has completed the repurchase of 4,758,000 shares, representing 0.53% for $4,081.98 million under the buyback announced on December 9, 2024.
Tranche Update on Eli Lilly and Company's Equity Buyback Plan announced on December 9, 2024.
Published on 02/12/2026 at 01:59 pm EST


















